Careteq (ASX:CTQ) 3-Year RORE % : -64.29% (As of Dec. 2025)


What is Careteq 3-Year RORE %?

Careteq ASX:CTQ 3-Year RORE % is -64.29 as of Dec. 2025. The stock has 6 warning signs investors should review. Among 605 Healthcare Providers & Services companies, Careteq ranks worse than 84.79% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Careteq's 3-Year RORE % for the quarter that ended in Dec. 2025 was -64.29%.

The industry rank for Careteq's 3-Year RORE % or its related term are showing as below:

ASX:CTQ's 3-Year RORE % is ranked worse than
84.79% of 605 companies
in the Healthcare Providers & Services industry
Industry Median: 0.07 vs ASX:CTQ: -64.29

Careteq  (ASX:CTQ) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Careteq 3-Year RORE % Related Terms


Careteq 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Careteq's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Careteq 3-Year RORE % Chart

Careteq Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
0.00 0.00 0.00 0.00 -65.91

Careteq Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 -20.45 -65.91 -64.29

ASX:CTQ vs VEEV, BTSG, TEM: 3-Year RORE % Comparison

For the Health Information Services subindustry, Careteq's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Careteq 3-Year RORE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Careteq's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Careteq's 3-Year RORE % falls into.



Careteq 3-Year RORE % Calculation

Careteq's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -0.001--0.019 )/( -0.028-0 )
=0.018/-0.028
=-64.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -64.29 mean?
Careteq (ASX:CTQ) has a 3-Year RORE % of -64.29 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Careteq and its competitors. According to the industry distribution chart, Careteq ranks #513 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 84.8%.
Is Careteq's 3-Year RORE % too high?
Careteq's current 3-Year RORE % is -64.29. Based on the distribution chart, Careteq ranks #513 out of 605 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Careteq's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Careteq ranks #513 out of 605 companies for 3-Year RORE %. This places Careteq in the lower half of its industry. The industry median 3-Year RORE % is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.07, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Careteq and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Careteq's current 3-Year RORE % is -64.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Careteq stock overvalued right now?
Based on GuruFocus' analysis, Careteq (ASX:CTQ) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading 20% above its estimated fair value. The current 3-Year RORE % is -64.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Careteq (ASX:CTQ), the current 3-Year RORE % is -64.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Careteq Business Description

Address 99 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
Careteq Ltd provides Residential Medication Management Review and Home Medicines Review services as part of the Medication Management Programs, generating revenue from medication review, education, and support services. The company focuses on medication management and home care solutions to provide continuity of care and improve clinical outcomes for patients through Home Medication Reviews. Medication-related harm includes adverse drug reactions, medication errors, and complications that jeopardise patient safety and increase healthcare costs. The company operates in Australia.